A Phase II Trial of Fractionated Vinorelbine/Doxorubicin as First-line Therapy for Advanced Breast Cancer

References

• Early Breast Cancer Trialists Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy (1992). Lancet, 339, 1–15, 71–85.
   Google Scholar
• Ross, M. B., Budzar, A. U. and Smith, T. L. (1985). Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer, 55, 341–346.
   PubMed Web of Science ®Google Scholar
• Bielack, S. S., Erttmann, R., Kempf -Bielack, B. and Winkler, K. (1996). Impact of scheduling on toxicity and clinical efficacy of doxorubicin: What do we know in the mid-nineties? Eur. J. Cancer, 32A(10), 1652–1660.
   PubMed Web of Science ®Google Scholar
• Gehl, J., Boesgaard, M., Paaske, T., Vittrup Jensen, B. and Dombernowsky, P. (1996). Combined doxorubicin and paclitaxel in advanced breast cancer: Effective and cardiotoxic. Ann. Oncol., 7, 687–693.
   PubMed Web of Science ®Google Scholar
• Weiss, A. J., Metter, G. E. and Fletcher, W. S. (1976). Studies of adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat. Rep., 60(7), July.
   Google Scholar
• Ritch, P. S., Occhipinti, S. J. and Skramstad, K. S. (1982). Increased relative effectiveness of doxorubicin against slowly proliferating sarcoma 180 cells after prolonged drug exposure. Cancer Treat. Rep., 66, 1159–1168.
   PubMedGoogle Scholar
• Chlebowki, R., Paroly, W. and Pugh, R. (1980). Adriamycin given as a weekly schedule without a loading course: Clinically effective with reduced incidence of cardiotoxicity. Cancer Treat. Rep., 64, 47–51.
   PubMedGoogle Scholar
• Lokich, J., Auerbach, M., Smith, L., Cantrell, J., Fryer, J. and Alt, D. (1992).A comparative trial of three schedules for single-agent doxorubicin in advanced breast cancer: An aborted investigation. J. Infus. Chemother., 2, 185–188.
   Google Scholar
• Fumoleau, P., Delgado, F., Delozier, T., Monnier, A., Gil Delgado, M., Kerbrat, P., Garcia-Giralt, E., Keiling, R., Namer, M., Closon, M., Goudier, M., Chollet, P., Lecourt, L. and Montcuquet, P. (1993). Phase II trial of weekly intravenous vinorelbine in first-line advanced breast chemotherapy. J. UM. Oncol., 11, 1245–1252.
   PubMed Web of Science ®Google Scholar
• Spielmann, M., Dorval, T., Turpin, F. and Antoine, E. (1994). Phase II trial of vinorelbine/doxorubicin as first line therapy of advanced breast cancer. J. Clin. Oncol., 12, 1764–1770.
   PubMed Web of Science ®Google Scholar
• Blajman, C., Balbiani, L., Coppola, F. and Bader, M. (1999). A prospective, randomised phase III trial comparing combination chemotherapy with cyclophosphamide, and 5-fluorouracil with navelbine plus doxorubicin in the treatment of advanced breast cancer. Cancer, 85, 1091-1097, 1999.
   Google Scholar
• Miller, A. B., Hoogstraten, B. and Stagnet, M. (1981). Reporting results of cancer treatment. Cancer, 47, 207-214, 1981.
   Google Scholar
• Chabner, B. and Collins, J. (Eds) (1990). Cancer Chemotherapy: Principles and Practice. Lippincott.
   Google Scholar
• Torti, F., Bristow, M. and Howes, A. (1983). Reduced cardiotoxicity of doxorubicin delivery on a weekly schedule. Assessment by endomyocardial biopsy. Ann. Intern. Med., 99, 745–749.
   PubMed Web of Science ®Google Scholar
• Carmichael, J., Hegg, R., Firat, D., Pawlicki, M., Delgado, R, Hill, S., Danel, P. and Le Bras, F. (1997). Navelbine and fractionated dose doxorubicin improves first line advanced breast cancer chemotherapy. An overview of 3 phase II trials. Eur. J. Cancer, 33 (Suppl 8), Abstract 649, S146.
   Google Scholar
• Vorobiof, D., Goedhals, L., Barnardt, P., Gudgeont, A., van der Merwe, A., Smith, L., Murray, E., Pretorius, D., Bassompierre, P., Bergonzoli, E., Delgado, F., Le Pape, I., Burillon, J. and Le Couturier, S. (1997). Phase II study of IV navelbine and doxorubicin in previously untreated advanced breast cancer. Proc. Am. Soc. Clin. Oncol., 16, Abstract 693, 197.
   Google Scholar
• Norris, B., Pritchard, K., James, K., Myles, J., Bennett, K., Marlin, S., Skillings, J., Findlay, B., Goss, P., Latreille, J., Lopez, P., Osoba, D. and Rodgers, A. (1996). A phase III comparative study of vinorelbine combined with doxorubicin vs. doxorubicin alone in metastatic/recurrent breast cancer. Proc. Am. Soc. Clin. Oncol., 15, Abstract 59, 98.
   Google Scholar
• Hochster, H. (1995). Combined doxorubicin/ vinorelbine (Navelbine) therapy in the treatment of advanced breast cancer. Semin. Oncol., 22 (Suppl 5), 55–60.
   PubMedGoogle Scholar
• Costa, M., Cabral-Filho, S., Correa, M., Yamaguchi, N., Novaes, N., Andrade, C., Agnelli, A., Rodrigues, T., Malzyner, A., Caponero, R., Delgado, G., Perdicaris, M., Martinez, A., Fraga, J., Le Pape, I., Delgado, F. and Hegg, R. (1996). Phase II study of sequential Navelbine and doxorubicin for the treatment of metastatic breast cancer: Preliminar results. Proc. Am. Soc. Clin., 15, Abstract 65, 100.
   Google Scholar
• Firat, D., Baltali, E., NH, R, Berk, O., Uskent, N., Danel, P., Le Pape, I. and Delgado, F. (1996). Navelbine and doxorubicin combination (D1-D8) in advanced breast carcinoma previously untreated. Ann. Oncol., 7, Abstract 108P, 25.
   Google Scholar
• Pawlicki, M., Siedlecki, P., Zaluski, A., Ramlau, R., Rolski, J., Burillon, J., Le Bras, F., Delgado, F. and Maj, S. (1996). A multicenter phase II study of Navelbine and doxorubicin as first line chemotherapy in advanced breast cancer: Preliminary results. Ann. Oncol., 7, Abstract 114P, 26.
   Google Scholar
• Lefrack, E., Pitha, J. and Rosenheim, S. (1973). A clinico-pathologic analysis of adriamycin cardiotoxicity. Cancer, 32, 302–314.
   PubMed Web of Science ®Google Scholar
• Gundersen, S., Kvinnsland, S., Klepp, O., Kvaloy, S., Lunds, E. and Host, H. (1986). Weekly adriamycin versus VAC in advanced breast cancer. A randomised trial. Eur. J. Clin. Oncol., 22, 1431–1434.
   PubMedGoogle Scholar
• Weiss, A., Metter, G., Fletcher, W., Wilson, W., Grage, T. and Ramirez, G. (1976). Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat. Rep., 60, 813–822.
   PubMedGoogle Scholar
• Gianni, L., Munzone, E. and Capri, G. (1995). Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumour efficacy and cardiac effects in a dose-finding and sequence-finding study. J. Clin. Oncol., 13, 2688–2699.
   PubMed Web of Science ®Google Scholar
• Nisticô, C., Garufi, C., Barni, S., Galla, D., Giannarelli, D., Vaccaro, A., D'ottavio, A. and Terzoli, E. (1999). Phase II study of epirubicin and vinorelbine with granulocyte colony-stimulating factor: A high-activity, dose dense weekly regimen for advanced breast cancer. Ann. Oncol., 10, 937–942.
   PubMed Web of Science ®Google Scholar